PASG News and Press, Passage Bio Inc. From 12/14/22

Interim safety data up to 20 months showed the low and high dose of PBGM01 were well tolerated and had a favorable safety profile Intra-cisterna magna administration of PBGM01 resulted in dose-dependent increases in CSF β-Gal activity and decreases in CSF GM1 gangliosides ...

The following slide deck was published by Passage Bio, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Passage Bio, Inc. 2022 Q3 - Results - Earnings Call Presentation

Passage Bio, Inc. (PASG) Q3 2022 Earnings Conference Call November 10, 2022, 8:30 AM ET Company Participants Stuart Henderson - VP, Corporate Development and Investor Relations William Chou - Chief Executive Officer Mark Forman - Chief Medical Officer Simona ...

Passage Bio press release ( NASDAQ: PASG ): Q3 GAAP EPS of -$0.49 beats by $0.31 . Cash, cash equivalents and marketable securities were $213.8 million as of September 30, 2022, as compared to $239.3 million as of June 30, 2022. The Company expects current cash an...

Dosed first patient in final cohort, Cohort 4, in dose-ascending phase of Imagine-1 clinical trial for GM1 gangliosidosis; expect to dose the final patient in this phase of the trial by year-end Plan to report initial safety and biomarker data from Cohorts 2 and 3 of Imagine-1 t...

PHILADELPHIA, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., chief executive officer, will ...

PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast at 8:3...

Genetic medicines company Passage ( NASDAQ: PASG ) appointed William Chou CEO and a board member, effective immediately. Chou, most recently, served as CEO of the clinical-stage biopharmaceutical company Aruvant Sciences. Chou replaces interim CEO Edgar ...

PHILADELPHIA, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc . (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced the appointment of William Chou, M.D. as chief exe...

PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that Simona King, chief financial officer of Passage B...